LDLR and familial hyperaldosteronism: Gain‐of‐function (GOF) mutations in the PCSK9 gene account for 1% of reported FH cases, such mutations increase the destruction of LDLR on the hepatocyte surface and accordingly result in an increase in levels of circulating LDL‐C.3